Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 41

    1.

    Update on gastrointestinal radiopharmaceuticals and dosimetry estimates.

    Knight LC.

    Semin Nucl Med. 2012 Mar;42(2):138-44.

    PMID:
    22293168
    [PubMed - in process]
    2.

    Liver function testing with nuclear medicine techniques is coming of age.

    Bennink RJ, Tulchinsky M, de Graaf W, Kadry Z, van Gulik TM.

    Semin Nucl Med. 2012 Mar;42(2):124-37.

    PMID:
    22293167
    [PubMed - in process]
    3.

    Guest editorial: gastrointestinal nuclear medicine: are we making progress?

    Maurer AH.

    Semin Nucl Med. 2012 Mar;42(2):74-5. No abstract available.

    PMID:
    22293161
    [PubMed - in process]
    4.

    Letter from the Editors: planar imaging in the age of SPECT.

    Freeman LM, Blaufox MD.

    Semin Nucl Med. 2012 Jan;42(1):1-2. No abstract available.

    PMID:
    22117807
    [PubMed - in process]
    5.

    Redesigning the nuclear medicine reading room.

    Zemariame N, Knight N, Siegel EL.

    Semin Nucl Med. 2011 Nov;41(6):463-71. Review.

    PMID:
    21978448
    [PubMed - indexed for MEDLINE]
    6.

    Synthetic positron emission tomography-computed tomography images for use in perceptual studies.

    D'Alessandro B, Madsen M, Samei E, Li X, Wooi-Tan J, Berbaum KS, Schartz K, Caldwell R, Zuckier LS.

    Semin Nucl Med. 2011 Nov;41(6):437-48. Review.

    PMID:
    21978446
    [PubMed - indexed for MEDLINE]
    7.

    Letter from the editors: image perception in nuclear medicine.

    Freeman LM, Blaufox MD.

    Semin Nucl Med. 2011 Nov;41(6):389. No abstract available.

    PMID:
    21978441
    [PubMed - indexed for MEDLINE]
    8.

    Computer-aided diagnosis and artificial intelligence in clinical imaging.

    Shiraishi J, Li Q, Appelbaum D, Doi K.

    Semin Nucl Med. 2011 Nov;41(6):449-62. Review.

    PMID:
    21978447
    [PubMed - indexed for MEDLINE]
    9.

    (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.

    Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP.

    Semin Nucl Med. 2011 Jul;41(4):314-21. doi: 10.1053/j.semnuclmed.2011.02.001. Review.

    PMID:
    21624565
    [PubMed - indexed for MEDLINE]
    10.

    The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease.

    Yu M, Nekolla SG, Schwaiger M, Robinson SP.

    Semin Nucl Med. 2011 Jul;41(4):305-13. doi: 10.1053/j.semnuclmed.2011.02.004. Review.

    PMID:
    21624564
    [PubMed - indexed for MEDLINE]
    11.

    Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

    Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM.

    Semin Nucl Med. 2011 Jul;41(4):300-4. doi: 10.1053/j.semnuclmed.2011.03.001.

    PMID:
    21624563
    [PubMed - indexed for MEDLINE]
    12.

    Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

    Vallabhajosula S.

    Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Review.

    PMID:
    21624562
    [PubMed - indexed for MEDLINE]
    13.

    The next generation of positron emission tomography radiopharmaceuticals in oncology.

    Rice SL, Roney CA, Daumar P, Lewis JS.

    Semin Nucl Med. 2011 Jul;41(4):265-82. Review.

    PMID:
    21624561
    [PubMed - indexed for MEDLINE]
    14.

    A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?

    Vallabhajosula S, Solnes L, Vallabhajosula B.

    Semin Nucl Med. 2011 Jul;41(4):246-64. doi: 10.1053/j.semnuclmed.2011.02.003. Review.

    PMID:
    21624560
    [PubMed - indexed for MEDLINE]
    15.

    Guest Editorial: new PET radiopharmaceuticals as molecular imaging probes.

    Vallabhajosula S.

    Semin Nucl Med. 2011 Jul;41(4):244-5. doi: 10.1053/j.semnuclmed.2011.03.002. No abstract available.

    PMID:
    21624559
    [PubMed - indexed for MEDLINE]
    16.

    Letter from the editors: positron emission tomography radiopharmaceuticals-current status.

    Freeman LM, Blaufox MD.

    Semin Nucl Med. 2011 Jul;41(4):243. doi: 10.1053/j.semnuclmed.2011.03.005. No abstract available.

    PMID:
    21624558
    [PubMed - indexed for MEDLINE]
    17.

    Evolution of brain imaging instrumentation.

    Abraham T, Feng J.

    Semin Nucl Med. 2011 May;41(3):202-19. Review.

    PMID:
    21440696
    [PubMed - indexed for MEDLINE]
    18.

    Letter from the editors: Dedicated imaging devices.

    Freeman LM, Blaufox MD.

    Semin Nucl Med. 2011 May;41(3):149-50. No abstract available.

    PMID:
    21440692
    [PubMed - indexed for MEDLINE]
    19.

    Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.

    Abraham T, Schöder H.

    Semin Nucl Med. 2011 Mar;41(2):121-38. Review.

    PMID:
    21272686
    [PubMed - indexed for MEDLINE]
    20.

    The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome.

    Silberstein EB.

    Semin Nucl Med. 2011 Mar;41(2):113-20. Review.

    PMID:
    21272685
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk